Therefore, it was hypothesized that low DAP3 expression might reduce sensitivity to 5-FU and oxaliplatin in gastric cancer and DAP3 was proposed as a potential molecular marker to predict the efficiency and prognosis of preoperative chemotherapy in patients treated with combined chemotherapy for gastric carcinoma (19). The gene discussed is DAP3; the disease is gastric carcinoma.